RxDoctor Payments Data

Rosa Diring

Family · Norfolk, VANPI 1326011974

Payments from drug & device makers

$5,666in general payments, 2019–2025

Across 189 payments — averaging $29.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$4K
  • Gilead$1K
  • Merck$129
  • CSL Behring$25
  • Novo Nordisk$25
  • Johnson & Johnson$23

What the payments were for

  • Food & beverage$5,646100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Viiv Healthcare Company115$4,066
Gilead63$1,398
Merck8$129
CSL Behring1$25
Novo Nordisk1$25
Johnson & Johnson1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,666 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$14,180
Medicare patients
73
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala1,059$4,294,770
OdefseyEmtricitab/Rilpiviri/Tenof Ala207$734,590
DovatoDolutegravir Sodium/Lamivudine234$712,227
TriumeqAbacavir/Dolutegravir/Lamivudi177$686,845
GenvoyaElviteg/Cob/Emtri/Tenof Alafen167$644,319
DescovyEmtricitabine/Tenofov Alafenam176$405,250
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf72$341,420
TivicayDolutegravir Sodium127$297,338
JulucaDolutegravir/Rilpivirine77$266,306
PrezcobixDarunavir/Cobicistat88$218,152
RukobiaFostemsavir Tromethamine15$183,260
IsentressRaltegravir Potassium49$98,875
EvotazAtazanavir Sulfate/Cobicistat27$45,890
EdurantRilpivirine Hcl24$34,783
Etravirine15$23,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$1,398$5,344,3391,402 claims
Viiv Healthcare CompanyDovato, Triumeq, Tivicay, Juluca, Rukobia$4,066$2,145,977630 claims
Johnson & JohnsonPrezcobix$23$218,15288 claims
MerckIsentress, Pifeltro$129$119,65161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →